Your browser does not support java script. Skip navigation
Loading, please wait  Loading, please wait...

11th Northeast Regional Hematology / Oncology Pharmacists Symposium


                                                               
                                                                                                 Boston Marriott Burlington Hotel Exterior    
     October 13 (Fri) & October 14 (Sat) 2017
 
     Marriott Hotel
    One Burlington Mall Road
    Burlington, MA 01803
                                                                                           
 
         
   
This two-day regional forum brings together medical and business professionals from the healthcare industry with the main focus of improving cancer care for their patients.  It is designed specifically for clinical pharmacy practitioners and health care professionals that specialize in hematology/oncology.  Attendees will be offered 13 ACPE and Nursing accredited sessions presented by experts in the field.
 
The 11th regional symposium will be held at the centrally located, beautifully appointed, Marriott Hotel in Burlington on Friday, October 13 from 9:00 a.m. – 8:00 p.m. and Saturday, October 14 from 7:00 a.m. – 4:40 p.m.  Buffet lunches included both days; Friday attendees are invited to join our welcome reception and delicious buffet dinner. Saturday morning continental breakfast will be provided.
 
Concurrent sessions offered.
  • Now 16 sessions providing an opportunity to earn 13 credits
  • On Friday at 2:30 p.m. you may attend either a seminar on Myeloma or Value Based Reimbursement.
  • On Saturday at 9:00 a.m. we are offering the topics Breast Cancer or CINV and at 10:15 a.m. you can choose to attend either a seminar n NSCLC or Lymphoma.
The choice is up to you on the day of the event.
 
This program is designed to meet the educational needs of pharmacists, nurses and
other interested healthcare professionals specializing in hematology/oncology practice.
Earn up to 13 Contact Hours including 2 hours Law.
 
Secure your overnight reservations by September 28, 2017. Call 888-855-7741 and mention code “NEHOPS” for a special rate of $169.00/night or on-line registrations at www.burlingtonmarriott.com

Date: Oct 13, 2017 09:50 AM - Oct 14, 2017 04:40 PM

Fee

$150.00

CE Hours

16.00

CE Units

1.600

Registration closes on Oct 12, 2017 11:00 PM

Target Audience(s)

  • Pharmacists & Nurses

Accreditation(s)

California Board of Nursing
 
American Health Resources, Inc. is approved by the California Board of Registered Nursing, Provider Number CEP 14254. Programs approved by CA BRN are accepted by most State Boards of Nursing; please check with licensing board to verify credits can be claimed in your state.
Accreditation Council for Pharmacy Education
American Health Resources is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education

Requirements for CE Credit

  • Participant Requirement and Statement of Credit: To receive credit, participants must fully attend each session (no partial credit will be awarded), pass in a completed attendance verification form, and using the access code provided, complete the online evaluation for each session attended. Attendance will be verified. All participants will have the opportunity to evaluate the educational sessions and presenters as well as the ability to identify their future educational needs. 
  • Pharmacists: CE credit will be automatically uploaded to CPE Monitor upon completion of the evaluation and posted to the participant’s NABP account within 72 hours where an official certificate of credit can be printed. Evaluations must be completed within 60 days of program date to receive credit.  
  • Starting January 1, 2018 ACPE will be charging a $200 fee for any credits submitted into the CPE Monitor after 60 days.  It is the participant’s responsibility to complete all activity evaluations and confirm that credits are in the CPE Monitor after attending an activity.
  • Statement of Disclosure: Disclosure will be made on the day of the program regarding any interest or affiliation a speaker may have with a supporting organization.
  • Refund Policy: A full refund will be provided only if a written request is received by American Health Resources, Inc. at least 48 hours prior to the program or if the program is cancelled. American Health Resources, Inc. reserves the right to change the presenters, topics or seminar schedules.
Only Certificates of Credit issued from CPE Monitor are valid in the US
  CPE Monitor will not accept credits after 60 days from the session date

Please choose a Fee Type from the Drop Down Menu Below:
I am a
 

 

 

   

Utilizing pharmacogenomics to guide chemotherapy drug and dosage selection allows for the reduction of severe and sometimes fatal adverse effects. During this presentation, the speaker will summarize the most commonly actionable pharmacogenomics variants as they relate to the oncology patient. A brief overview of pharmacogenomics educational resources will also be provided.
Knowledge Based

Objectives

  • Summarize the difference between germline and somatic genetic testing.
  • Discuss the pharmacogenes that are important in oncology.
  • Describe an example of pharmacogenomic implementation in an oncology setting.
  • Discuss and identify the pharmacogenomic educational resources.

Speaker(s)/Author(s)

Cyrine-Eliana Haidar picture

Cyrine-Eliana Haidar, PharmD, BCPS, BCOP
Clinical Pharmacogenetics Coordinator, St. Jude Children's Research Hospital


Brief Bio : Cyrine Eliana Haidar, PharmD, BCPS, BCOP, is the Clinical Pharmacogenetics Coordinator at St. Jude Children’s Research Hospital, where several medications are prescribed or dosed based on a patient’s genotype. Working with a multidisciplinary team, Haidar coordinates moving pharmacogenetic test results into a patient’s electronic medical record (EMR), allowing physicians and other members of the health care team to make medication decisions tailored to each patient. She is also responsible for developing education materials about pharmacogenetic tests and developing competencies and guidelines for implementing pharmacogenetics in clinical practice. “Pharmacists are the medication experts, and our understanding of medications and doses allows us to be perfectly placed to make decisions about medication use based on a patient’s pharmacogenetic status,” said Haidar, who has been with St. Jude for 9 years.

Activity Number

0280-0000-17-065-L01-P
Date: 10/13/17
Time: 09:50 AM - 10:50 AM

CE Hours

1.00
   

   

The goal of personalized medicine is to provide individualized treatment and to predict the clinical outcome of different treatments in different patients. Pharmacogenomics is one of the core elements in personalized medicine. The basic concept is that inter-individual variability in drug response is a consequence of multiple factors, including genomics, epigenomics, the environment and a patient's characteristics, such as gender, age and/or concomitant medications.  Most cancers are driven by genomic alterations that dysregulate key oncogenic pathways influencing cell growth and survival.  Over the past several years, the convergence of discovery, technology, and therapeutic development has created an unparalleled opportunity to test the hypothesis that systematic knowledge of genomic, transcriptomic, metabolomic, and proteomic information from individual tumors can improve clinical outcomes for many patients with cancer.  The routine use of molecular testing to guide treatment selection and the incorporation of pharmacogenomics to further personalize the treatment is the next frontier in cancer therapeutics.
Knowledge Based

 

Objectives

  • Describe current state of the art of cancer genomics.
  • Discuss challenges of implementing precision oncology in clinical practice.
  • Summarize literature around combining multiple therapeutic agents.
  • Discuss current understanding of the costs of cancer genomics and strategies to reduce barriers to care.

Speaker(s)/Author(s)

Casey Williams, PharmD, BCOP picture

Casey Williams, PharmD, BCOP
Director, Avera Center for Precision Oncology


Brief Bio : Dr. Casey Williams is the Director of the Avera Cancer Institute Center for Precision Oncology and the Department of Molecular and Experimental Medicine at the Avera Cancer Institute in Sioux Falls, SD. Dr. Williams received his Pharm.D. from Creighton University and subsequently completed his PGY-1 residency in Pharmacy Practice at the University of North Carolina, and his PGY-2 Oncology Practice residency at the University of Texas/Audie Murphy VA. Dr. Williams has clinical faculty appointments at the University of Kansas School of Pharmacy, South Dakota State University School of Pharmacy and the University of South Dakota School Of Medicine. His current research focus is in cancer genomics and translational therapeutics to better understand the role that specific genes have on the activity of various treatments for the treatment of cancer.

Activity Number

0280-0000-17-066-L01-P
Date: 10/13/17
Time: 11:00 AM - 12:00 PM

CE Hours

1.00
   

   

This presentation will distinguish between reference biologics and biosimilars.  It will define the differences between extrapolation and interchangeability.  In addition, an update of all the FDA guidance’s and where they stand will be described.   The program will also review all currently FDA approved biosimilars and where they stand in the market plus talk about what products are in the pipeline and what to expect over the next couple of years.
Knowledge Based

Objectives

  • Describe the science behind biologic and biosimilar manufacturing and commercialization.
  • List 3 key factors for biosimilars that will allow for therapeutic interchange in your institution.
  • List 3 of the most recent FDA guidance’s on biosimilars and how they may affect use in your institution.
  • List the current FDA approved biosimilars and explain what their impact on the US market has been.
  • Describe the current biosimilar pipeline and what products we can expect out in the next year or so.

Speaker(s)/Author(s)

Jim Koeller, MS picture

Jim Koeller, MS
Professor, Pharmacotherapy Division, University of Texas at Austin College of Pharmacy


Brief Bio : Professor Koeller received his undergraduate and graduate degrees from the University of Wisconsin-Madison, and completed a residency at the University of Wisconsin Hospital. Professor Koeller is currently a full professor and member of the Center for Pharmacoeconomic Studies in the College of Pharmacy at the University of Texas at Austin, where he holds the Eli Lilly/CR Sublett Endowed Fellowship in Pharmacy. In addition, Professor Koeller is an Adjoint Professor of Medicine and Oncology at the University of Texas Health Science Center in San Antonio. Prior to moving to Texas, he spent 5 years coordinating the Phase I Drug Development Program in the Department of Human Oncology, Wisconsin Comprehensive Cancer Center in Madison, Wisconsin. Professor Koeller’s research interests are in the areas of pharmacoeconomics, outcomes and health services research. A significant portion of his research is in the area of oncology. His team has established the cost of care for non-small cell lung cancer, breast cancer and head and neck cancer. His team has also quantitated the value of using pathways in oncology, identified risk groups in the aids population and established the clinical utility of genomics testing in the Medicare population. He has published over 250 articles, abstracts, and book chapters in the areas of oncology practice, pharmacoeconomics, new drug development, and supportive care issues of the cancer patient. In addition, he has given over 500 presentations related to oncology, supportive care, biosimilars, pharmacoeconomics, cancer disease management, pathway development and outcome measurement, quality & value in cancer care, and general cancer care economics.

Activity Number

0280-0000-17-067-L03-P
Date: 10/13/17
Time: 01:05 PM - 02:05 PM

CE Hours

1.00
   

   

The addition of new lenalidomide-and bortezomib-based drug regimens for patients with multiple myeloma increases the complexity of pharmacotherapeutic strategies, which must balance response benefit with tolerability. There are a number of comorbidities and treatment-related adverse events that must be appropriately assessed and monitored for, to ensure patient safety and prevent premature discontinuation of therapy. In this activity, participants will learn about various comorbid conditions, including hepatic and renal dysfunction, diabetes, and cardiovascular dysfunction, which can impact pharmacy-related decisions such as dose-modification, treatment interruption, or administration of concomitant medications.
Knowledge Based

Objectives

  • Recognize treatment-related adverse events associated with new drug regimens used to treat patients with multiple myeloma.
  • Identify comorbid conditions and overlapping drug toxicities that warrant pharmacotherapeutic intervention in patients with multiple myeloma.
  • Outline pharmacotherapeutic strategies for managing adverse events in comorbid patients with multiple myeloma.

Speaker(s)/Author(s)

R. Donald Harvey, PharmD, FCCP, BCOP picture

R. Donald Harvey, PharmD, FCCP, BCOP
Assistant Professor, Hematology/Medical Oncology, Director, Phase 1 Clinical Trials Section, Winship Cancer Institute of Emory University


Brief Bio : R. Donald Harvey, PharmD, is Assistant Professor of Hematology and Medical Oncology and Pharmacology at the Winship Cancer Institute of Emory University. A Board Certified Oncology Pharmacist, Dr. Harvey serves as director of the Winship Cancer Institute's Phase I Clinical Trials Unit and Section and as chair of the Data and Safety Monitoring Committee. He is a Fellow of the American College of Clinical Pharmacy and a Fellow of the Hematology/Oncology Pharmacy Association.

Activity Number

0280-0000-17-068-L01-P
Date: 10/13/17
Time: 02:30 PM - 03:30 PM

CE Hours

1.00
   

   

*** Satelite Session ***
Formal title, presenter, objectives and summary to be posted soon.
Date: 10/13/17
Time: 02:30 PM - 03:30 PM

CE Hours

1.00
   

   

This lecture will summarize a number of advances in treating CLL, which will impact an estimated 20,110 new diagnoses and an estimated 4,660 deaths in the United States in 2017, representing approximately one-quarter of all leukemia diagnoses.  Emphasis will be placed on the incorporation of targeted therapy agents either alone or in combination with standard cytotoxic agents.  Primary literature will be reviewed for first-line, salvage therapy and maintenance therapy for CLL with the resultant implication for development of treatment guidelines.  The role for pharmacists in providing appropriate supportive care measures and promoting adherence with oral regimens for the treatment of CLL will be summarized.
Knowledge Based 

Objectives

  • Describe the impact of age, comorbidities and cytogenetics on the management of CLL.
  • Discuss state of the art clinical trial data for efficacy and toxicity of new and emerging therapeutic options for the management of CLL in the front-line, salvage and maintenance settings.
  • Articulate general strategies to manage supportive care and address adherence for new oral targeted agents.

Speaker(s)/Author(s)

Christopher A. Fausel, PharmD, MHA, BCOP picture

Christopher A. Fausel, PharmD, MHA, BCOP
Clinical Manager, Oncology Pharmacy , Indiana University Simon Cancer Center


Brief Bio : Clinical Manager, Oncology Pharmacy, Indiana University Health; Chair, Hoosier Oncology Group

Activity Number

0280-0000-17-069-L01-P
Date: 10/13/17
Time: 04:00 PM - 05:00 PM

CE Hours

1.00
   

   

The purpose of this activity is to educate pharmacists on the changing landscape of treatment options for genitourinary cancers.   The presentation will discuss traditional modalities and evaluate the role of immuno-oncology in the genitourinary treatment paradigm.  The presentation will also focus on side effect management of agents used in treating genitourinary cancers.  
Application Based 

Objectives

  • Recognize the incidence and prevalence of genitourinary malignancies.
  • Discuss chemotherapy options for the treatment of genitourinary malignancies.
  • Evaluate the role of immuno-oncology in treating genitourinary malignancies.
  • Discuss current guideline based recommendations.

Speaker(s)/Author(s)

Adam Peele picture

Adam Peele, PharmD, MHA, BCPS, BCOP
Residency Program Director, Cone Health Cancer Center Pharmacy Manager, Cone Health Cancer Center


Brief Bio : Adam graduated from the University of North Carolina at Chapel Hill with a bachelor’s degree in history and received a doctorate of pharmacy degree from the Campbell University College of Pharmacy and Health Sciences. He completed both his post graduate year one pharmacy practice residency and his second year post graduate residency in hematology/oncology with the Cone Health System. He is a board certified pharmacotherapist and oncology pharmacist by the American College of Clinical Pharmacy. Adam’s current role is as an oncology pharmacy manager and clinical hematology/oncology pharmacy specialist with Cone Health.

Activity Number

0280-0000-17-070-L01-P
Date: 10/13/17
Time: 07:00 PM - 08:00 PM

CE Hours

1.00
   

 

   

Acute myeloid leukemia (AML) is characterized by clinical and biological heterogeneity. Despite the advances in our understanding of its pathobiology, the chemotherapy-directed management has remained largely unchanged in the past 40 years. However, various novel agents have demonstrated clinical activity, either as single agents (e.g., isocitrate dehydrogenase (IDH) inhibitors, vadastuximab) or in combination with standard induction/consolidation at diagnosis and with salvage regimens at relapse. The classes of agents described in this review include novel cytotoxic chemotherapies (CPX-351 and vosaroxin), FMS-like tyrosine kinase receptor 3 (FLT3) inhibitors, and  cell cycle inhibitors (volasertib), B-cell lymphoma 2 (BCL-2) inhibitors, and aminopeptidase inhibitors.  Here we summarize new and emerging therapies in the treatment of AML.
Application Based 

Objectives

  • Summarize molecular targets in the treatment of AML.
  • Evaluate the use of Flt-3 in AML patients for treatment.
  • Describe new agents in the treatment of AML.

Speaker(s)/Author(s)

Ali McBride, PharmD, MS, BCPS picture

Ali McBride, PharmD, MS, BCPS


Brief Bio : Clinical Coordinator Hematology/Oncology, The University of Arizona Cancer Center, Tucson, AZ

Activity Number

0280-0000-17-071-L01-P
Date: 10/14/17
Time: 07:45 AM - 08:45 AM

CE Hours

1.00
   

   

The purpose of this activity is to educate pharmacists on the current standard of care regimens as well as novel therapies used for the management of patients with early-stage and locally-advanced breast cancer.  Efficacy and toxicity of pharmacological therapies will be discussed, and current data to support the use of newly approved or novel therapeutic agents for the treatment of patients with early-stage and locally-advanced breast cancer will be reviewed.
Knowledge Based 

Objectives

  • Classify a breast cancer patient as a candidate for neoadjuvant or adjuvant therapies.
  • Summarize the data supporting systemic therapy options for patients with early-stage and locally-advanced breast cancer.
  • Recall the toxicities associated with therapeutic agents utilized in patients with early-stage and locally-advanced breast cancer.

Speaker(s)/Author(s)

Chad Barnett, PharmD, BCOP picture

Chad Barnett, PharmD, BCOP
Clinical Pharmacy Specialist - Breast Oncology, Division of Pharmacy, University of Texas M.D. Anderson Cancer Center


Brief Bio : Chad M. Barnett, PharmD, BCOP is Clinical Pharmacy Specialist in the Division of Pharmacy at The University of Texas M. D. Anderson Cancer Center in Houston, Texas. In addition to his patient care responsibilities, Dr. Barnett is involved in precepting Oncology Pharmacy Practice Residents on the Breast Medical Oncology Rotation. He has authored numerous book chapters and articles and has presented nationally on topics related to breast cancer and bone health in patients with cancer. Dr. Barnett is also actively involved in breast cancer research. Dr. Barnett received his Doctor of Pharmacy degree from the University of Kansas in Lawrence, Kansas. He completed a Pharmacy Practice Residency at The Methodist Hospital in Houston, Texas and an Oncology Pharmacy Practice Residency at the University of Texas M.D. Anderson Cancer Center in Houston, Texas. Dr. Barnett became a Board Certified Oncology Pharmacist (BCOP) in 2006.

Activity Number

0280-0000-17-072-L01-P
Date: 10/14/17
Time: 09:00 AM - 10:00 AM

CE Hours

1.00
   

   

The purpose of this activity is to educate pharmacists on current trends in supportive care in oncology topics including CINV and early palliative care interventions.
Knowledge Based

Objectives

  • Identify key changes in recent CINV guideline updates that impact an oncology patient’s plan of care.
  • Discuss the role of early palliative care in oncology and efforts to identify patient factors for implementation.

Speaker(s)/Author(s)

Bridget Scullion,  picture

Bridget Scullion, , PharmD, BCOP
Director of Clinical Pharmacy Services, Dana Farber Cancer Institute


Brief Bio : Director of Clinical Pharmacy Services, Dana-Farber Cancer Institute

Activity Number

0280-9999-17-078-L01-P
Date: 10/14/17
Time: 09:00 AM - 10:00 AM

CE Hours

1.00
   

   

The purpose of this activity is to educate pharmacists on the efficacy, toxicity, and place in therapy for EGFR and ALK inhibitors.  The talk will cover testing for the genetic mutations and new pivotal study data that may differentiate agents and discuss how they fit in the current guidelines.  This activity will also include a discussion of drug related toxicity as well as toxicity prevention and management
Knowledge Based 

Objectives

  • Identify the pros and cons of liquid biopsies when it comes to identifying driver mutations to select drug therapy.
  • Discuss the most recent clinical data in first and second line treatment with a targeted therapy so that the benefits and place in therapy can be discussed with patients and healthcare providers.
  • Describe common and unique toxicities associated with targeted therapies to optimize monitoring and patient counseling.

Speaker(s)/Author(s)

Val R. Adams, PharmD, FCCP, BCOP picture

Val R. Adams, PharmD, FCCP, BCOP
Associate Professor, Pharmacy Program Director, PGY2, Specialty Residency, Hematology/Oncology, University of Kentucky College of Pharmacy


Brief Bio : Dr. Adams is an Associate Professor in the department of Pharmacy Practice and Science in the College of Pharmacy at the University of Kentucky. He is on the graduate faculty and is a member of the Markey Cancer Center where he has a clinical practice site. As the director of the hematology / oncology residency program, he has trained thirty one residents and maintains an active research lab. He received his B.S. in pharmacy from the University of Utah and received his doctor of pharmacy from the University of Texas at Austin jointly with the University of Texas Health Science Center at San Antonio. He completed a residency in hematology / oncology at the Audie L. Murphy Memorial V.A. Hospital in San Antonio, Texas. He then completed a two-year fellowship in immunology and transplantation at the University of Florida. Following the completion of the fellowship he joined the University of Kentucky faculty in 1996.

Activity Number

0280-0000-17-073-L01-P
Date: 10/14/17
Time: 10:15 AM - 11:15 AM

CE Hours

1.00
   

   

*** Satelite Session ***
Formal title, presenter, objectives and summary to be posted soon.
Date: 10/14/17
Time: 10:15 AM - 11:15 AM

CE Hours

1.00
   

   

The purpose of this activity is to educate pharmacists and healthcare providers how they could help improve overall prognosis for ovarian cancer by knowing the signs/symptoms to direct patients for proper diagnostic screening and work-up that would lead to earlier diagnosis and treatment interventions.   We discuss the how modifications of regimens from initial intraperitoneal clinical trials may not equate to same clinical benefits.   This will also include discussion of balancing the benefits of targeted therapy and how to distinguish between the new PARP inhibitors.   Finally since prevention of adverse side effects, supportive care and proactive management of common complications of ovarian is essential to optimize patient quality of life, clinical pearls and lessons learned will be discussed throughout the presentation.
Knowledge Based 

Objectives

  • Summarize the challenges in the diagnosis and overall prognosis of ovarian cancer.
  • Recognize the current role of intraperitoneal chemotherapy for the treatment of ovarian cancer.
  • Discuss the evolution and limitations of targeted therapy being integrated into the treatment of advanced ovarian cancer.
  • Review the prevention and management of common disease and treatment complications observed in advanced ovarian cancer patients.

Speaker(s)/Author(s)

Judith A. Smith picture

Judith A. Smith, PharmD, BCOP, CPHQ, FCCP, FISOPP
Associate Professor, McGovern Medical School


Brief Bio : Dr. Judith A. Smith is an Associate Professor in the in the Department of Obstetrics, Gynecology and Reproductive Sciences at The University of Texas Health Science Center at Houston Medical School. She also has faculty appointments at the University of Houston, College of Pharmacy and the UT Graduate School of Biomedical Sciences. Dr. Smith received a Bachelor of Science in Pharmacy and her Doctor of Pharmacy degree from Union University Albany College of Pharmacy. She completed residency in Pharmacy Practice and Oncology Pharmacy Practice at the National Institutes of Health followed by a fellowship in Clinical Pharmacology at UTMDACC. Upon completion of her fellowship, she joined the Faculty at UT MD Anderson. She has been Board Certified in Oncology Pharmacy and Certified Professional in Healthcare Quality. Her research focus is on drug development for gynecologic cancers and women’s health conditions with a specific focus on integration of nutritional supplements and herbs with traditional western medicine.

Activity Number

0280-0000-17-074-L01-P
Date: 10/14/17
Time: 11:30 AM - 12:30 PM

CE Hours

1.00
   

   

This activity is intended to educate pharmacists on the recent updates and long-term data of various treatment regimens utilized in melanoma. Recent data suggests multiple treatment modalities may be effective in patients with metastatic melanoma with brain metastases. Ongoing research continues with new combination therapies for the treatment in melanoma, including new drug entities.  New approvals will be discussed including indications, study results, and side effects.  Cases will be presented to determine best treatment options for patient scenarios
Applicattion Based 

Objectives

  • Discuss recent updates in the treatment of melanoma.
  • Identify treatment options in patients with metastatic melanoma and brain metastases.
  • Evaluate the role of newer combination therapies.

Speaker(s)/Author(s)

LeAnn B. Norris, PharmD, BCPS, BCOP picture

LeAnn B. Norris, PharmD, BCPS, BCOP
Associate Professor, University of South Carolina College of Pharmacy


Brief Bio : Dr. LeAnn Norris completed her Pharm.D. degree at the University of South Carolina College of Pharmacy in Columbia in 2004. After graduation, she completed a PYG1 residency at the Moses Cone Health System in Greensboro, North Carolina. In 2006, she completed her PGY2 residency at the Regional Cancer Center within the Moses Cone Health System in Greensboro. Dr. Norris is now an associate professor at the South Carolina College of Pharmacy. She was the 2010 recipient of the Hematology/Oncology Pharmacy Association New Practitioner of the Year Award. Her research interests include supportive care, hospice/palliative care issues, and medication safety

Activity Number

0280-0000-17-075-L01-P
Date: 10/14/17
Time: 01:30 PM - 02:30 PM

CE Hours

1.00
   

   

Sarcomas are a rare type of cancer with many subtypes and very few therapies. The past has demonstrated little advancement in the treatment of these tumors. However, the past two years have made large strides in this area and new understandings into the biology of sarcomas are leading to exciting developments for the future.
Application Based 

Objectives

  • Identify the population of patients at risk for the development of various sarcomas.
  • Compare and contrast new agents for the treatment of sarcomas.
  • Describe the future direction of treatment in sarcomas.

Speaker(s)/Author(s)

Christy S. Harris  picture

Christy S. Harris , PharmD, BCPS, BCOP
Assistant Professor, Dana Farber Cancer Institute


Brief Bio : Associate Professor, MCPHS University, Clinical Pharmacy Specialist Education: University of Tennessee Health Sciences, Memphis, TN PGY-1 Training: University of Tennessee Medical Center, Knoxville, TN PGY-2 Training: Medical University of South Carolina, Charleston, SC

Activity Number

0280-9999-17-076-L01-P
Date: 10/14/17
Time: 02:35 PM - 03:35 PM

CE Hours

1.00
   

   

Since the tragic events of October 2012, surrounding the New England Compounding Center (NECC), multiple local, state and federal authorities have tried to put in place safeguards to protect the public health as it relates to the compounding of medications for patient use. The complex and often overlapping mosaic of guidance, statutes, and regulations from these multiple authorities have created a complex, confusing, and cumbersome environment for pharmacists and regulators alike. This session will attempt to unravel the multi-faceted landscape and provide practical reference, tools, and strategies for compounders address this often perplexing area of pharmacy practice.
Knowledge Based 

Objectives

  • Describe the current landscape of overlapping regulations that have an impact on compounding operations.
  • Describe the environmental control requirements for sterile and/or non-sterile compounding.
  • Outline strategies for managing the increasingly complex regulated environment while providing optimal patient care services

Speaker(s)/Author(s)

Lou Diorio  picture

Lou Diorio , RPh, FAPhA
Principal, LDT Health Solutions, Inc., Wayne, NJ


Brief Bio : With more than thirty years of practice in clinical settings, Lou Diorio, RPh, FAPhA, is a principal of LDT Health Solutions, Inc. (LDT), a medication safety and quality management consulting company serving clients nationwide. He is a graduate of Long Island University's Schwartz College of Pharmacy and Adjunct Professor of Pharmacy Practice for the College and a preceptor. Lou is a Fellow of the American Pharmacists Association (APhA), past Chair of APhA's Academy of Practice and Management, and past Chair of APhA's Compounding Special Interest Group (SIG). Published extensively, he lectures and develops educational materials for pharmaceutical companies on technical, regulatory, and marketing topics.

Activity Number

0280-0000-17-077-L03-P
Date: 10/14/17
Time: 03:40 PM - 04:40 PM

CE Hours

1.00